JP2023553854A5 - - Google Patents

Info

Publication number
JP2023553854A5
JP2023553854A5 JP2023533648A JP2023533648A JP2023553854A5 JP 2023553854 A5 JP2023553854 A5 JP 2023553854A5 JP 2023533648 A JP2023533648 A JP 2023533648A JP 2023533648 A JP2023533648 A JP 2023533648A JP 2023553854 A5 JP2023553854 A5 JP 2023553854A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
polypeptide
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553854A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/083659 external-priority patent/WO2022117595A2/en
Publication of JP2023553854A publication Critical patent/JP2023553854A/ja
Publication of JP2023553854A5 publication Critical patent/JP2023553854A5/ja
Pending legal-status Critical Current

Links

JP2023533648A 2020-12-02 2021-11-30 ドナー鎖補完性fimh Pending JP2023553854A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP20211337 2020-12-02
EP20211337.9 2020-12-02
EP20214942 2020-12-17
EP20214942.3 2020-12-17
PCT/EP2021/083659 WO2022117595A2 (en) 2020-12-02 2021-11-30 Novel antigens

Publications (2)

Publication Number Publication Date
JP2023553854A JP2023553854A (ja) 2023-12-26
JP2023553854A5 true JP2023553854A5 (enExample) 2024-11-15

Family

ID=78829624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533648A Pending JP2023553854A (ja) 2020-12-02 2021-11-30 ドナー鎖補完性fimh

Country Status (9)

Country Link
US (1) US20240115688A1 (enExample)
EP (1) EP4255919A2 (enExample)
JP (1) JP2023553854A (enExample)
KR (1) KR20230117166A (enExample)
AU (1) AU2021392894B2 (enExample)
CA (1) CA3202549A1 (enExample)
IL (1) IL303334A (enExample)
MX (1) MX2023006320A (enExample)
WO (1) WO2022117595A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020375214B2 (en) * 2019-11-01 2024-02-08 Pfizer Inc. Escherichia coli compositions and methods thereof
EP4448002A1 (en) * 2021-12-17 2024-10-23 Pfizer Inc. Polynucleotide compositions and uses thereof
CA3248209A1 (en) * 2022-05-25 2023-11-30 CureVac SE Escherichia coli Antigenic Polypeptide-Based Nucleic Acid Vaccine (FIMH)
CN121586722A (zh) * 2023-06-06 2026-02-27 辛泰伦有限责任公司 产生对细菌感染的免疫力的组合物和方法
JP2026521505A (ja) * 2023-06-14 2026-06-30 ファイザー・インク Rnaを安定化するための方法

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303A (en) 1849-04-10 And benjamin hallowell
US347A (en) 1837-08-08 dixon
US3238190A (en) 1963-10-23 1966-03-01 Madaus & Co K G Fa Dr Aescin recovery
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
WO1988009797A1 (en) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Autocrine motility factors in cancer diagnosis and management
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
PT729473E (pt) 1993-11-17 2001-02-28 Deutsche Om Arzneimittel Gmbh Dissacaridos de glucosamina metodo para a sua preparacao composicao farmaceutica contendo os mesmos e sua utilizacao
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
AU734180B2 (en) 1997-08-29 2001-06-07 Antigenics Llc Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
EP1089913A1 (fr) 1998-06-08 2001-04-11 SCA Emballage France Emballage a remise a plat rapide
SK287073B6 (sk) 1998-06-30 2009-11-05 Om Pharma N-Acyldipeptidový derivát, spôsob jeho prípravy a farmaceutický prostriedok, ktorý ho obsahuje
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
HK1045713A1 (zh) * 1999-07-13 2002-12-06 Medimmune, Inc. 供体链补体的菌毛蛋白和粘附素宽基疫苗
AU1581400A (en) 1999-12-22 2001-07-03 Om Pharma Acyl pseudopeptides bearing a functionalised auxiliary spacer
JP4331944B2 (ja) 2001-04-17 2009-09-16 大日本住友製薬株式会社 新規アデニン誘導体
DK1719511T3 (da) 2001-11-16 2009-04-14 Coley Pharm Group Inc N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methansulfonamid, en farmaceutisk sammensætning omfattende samme, og anvendelse deraf
JP2006517974A (ja) 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Irm化合物およびトル様受容体8に関する方法および組成物
KR100673872B1 (ko) * 2004-04-19 2007-01-25 학교법인 성균관대학 요로감염증의 예방 및 치료를 위한 재조합 디엔에이,플라스미드, 형질전환 미생물 및 경구용 백신 단백질
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
KR101684447B1 (ko) 2008-06-25 2016-12-08 인썸(인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰메디칼르) 면역애쥬번트인 플라겔린 기반의 화합물 및 이의 용도
US8778359B2 (en) 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
US10722580B2 (en) 2015-05-13 2020-07-28 University Of Washington Compositions and methods for treatment and prevention of uropathogenic E. coli infection
WO2020079586A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
AU2020375214B2 (en) * 2019-11-01 2024-02-08 Pfizer Inc. Escherichia coli compositions and methods thereof

Similar Documents

Publication Publication Date Title
JP7189014B2 (ja) Rsvに対するワクチン
JP6538622B2 (ja) ホモ二量体タンパク質コンストラクト
JP6679475B2 (ja) 安定化された可溶性融合前rsv fポリペプチド
JP6975709B2 (ja) 安定化したウイルスクラスi融合タンパク質
JP7088841B2 (ja) 安定化された可溶性融合前rsv fタンパク質
JP2022527235A5 (enExample)
JP6205359B2 (ja) ワクチン
CN115043915B (zh) 一种增强新冠病毒变异株免疫原性的方法及其应用
JP2024541466A5 (enExample)
KR20220057578A (ko) 인플루엔자 바이러스 백신 및 이의 용도
WO2017207477A1 (en) Stabilized pre-fusion rsv f proteins
WO2024103431A1 (zh) 一种增强新冠突变株疫苗广谱性的方法及新冠广谱疫苗
JP2021509254A (ja) H3n2亜型インフルエンザウイルスのヘマグルチニンタンパク質の突然変異体及びその使用
CN116034115B (zh) 疫苗组合物、方法及其用途
CN107344969B (zh) 一种纳米流感疫苗及构建方法和应用
JP6863966B2 (ja) 標的ポリペプチドを提示するためのポリペプチド担体及びその使用
MX2009003188A (es) Polipeptidos hibridos inmunogenicos antiobesidad y composicion de vacuna antiobesidad que comprende los mismos.
EP2773674A1 (en) Immunologic constructs and methods
CN109627295B (zh) 一种通用型狂犬病相关病毒g蛋白胞外段的制备方法
TW202317600A (zh) 預防多種病毒感染的多價疫苗
CN114409803B (zh) 流感病毒三聚体亚单位疫苗及其应用
KR20230035340A (ko) 안정화된 코로나 바이러스 스파이크 단백질 융합 단백질
JP2023510544A5 (enExample)
JP4797149B2 (ja) インフルエンザウイルスに対するベクターワクチン
CA3211034A1 (en) Stabilized pre-fusion rsv fb antigens